Scientists at The University of Nottingham are amassing an arsenal of ...It infiltrates hospitals as microscopic spores. Its defences are so... A research group led by Professor Nigel Minton in the Centre fo...The work funded by the Medical Research Council follows a scien... Until now scientists have understood very little about the b...
Scientists at The University of Nottingham are amassing an arsenal of weapons in preparation for a counter-offensive against the most deadly of hospital superbugs .
It infiltrates hospitals as microscopic spores. Its defences are so strong it can resist most antibiotics. And it kills three times as many people every year as MRSA.
A research group led by Professor Nigel Minton in the Centre for Healthcare Associated Infections (CHAI), with Dr Peter Mullany at University College, London have been awarded over 1.6m pounds for one of the country's largest studies into C.difficile (C. diff).
The work funded by the Medical Research Council, follows a scientific breakthrough by CHAI microbiologists that is set to revolutionise the genetic analysis of Clostridium difficile and its close relatives.
Until now scientists have understood very little about the biology of C-diff. With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Morvus Technology Ltd, Professor Nigel Minton and his team have developed the ClosTron knock out system which can target specific genes in C. diff and other clostridial species.
For the very first time scientists have an extremely rapid and effective way of identifying and deactivating the toxins and other factors that cause the disease and can begin the search for new therapies to prevent or cure it.
Professor Minton said: Although we have the entire genetic blueprint of C.diff, and have an inkling as to what bacterial factors might be important in disease, we have been unable to test these ideas. You never really know what a particular factor is doing until it isn't there. You need to be able to inactivate, 'knock-out', the gene responsible, and then see if the bacterium can still cause disease.
Until now 'knocking out' genes has been very difficult to do. Our breakthrough ClosTron technology now makes gene '"/>
(Date:11/25/2009)...ation and treatment clinics to resume Monday, Nov....ovember 25, 2009 -- Centegra Health System is cont...ne shots at four Centegra Primary Care (CPC) vacci...as arrived. The clinics are at CPC sites in Huntle... open as follows: , From 4:30 to 7:3...
(Date:11/25/2009)...ological symptoms, study finds , , WEDN...de effects are among the potential problems faced ...re treated with cisplatin-based chemotherapy, a ne...orwegian men treated for unilateral testicular can...w-up survey conducted from 1998 to 2002. , The ...
(Date:11/25/2009)...al cancer also can reverse a rare stomach disorder...he disease, researchers at Vanderbilt University M...se causes thickening of the stomach lining, severe...nemia and swelling in the feet and ankles due to p...stric cancer. Previously, the only effective treat...
...an research groups are undertaking pioneering stud...ing to patients receiving new drug treatments as e...fessor Shaun Jackson from The Australian Centre fo...tigating the impact of the bone marrow microenviro...
...arch 9, 2009 An easily implementable technique to...ed through angioplasty and stent insertion has bee...nsky of the Hebrew University of Jerusalem. , A... to part of the beating heart, usually due to plaq...
...n California Practice to Join SpectraScience Netwo...ystem , , SAN DIEGO, March 9 SpectraScience, Inc...dical device company, today announced that it has ... founder of Women,s Integrative Health, stated, "W...
...March 9 CEL-SCI Corporation (NYSE Alternext US: C...clusive licensing agreement with Byron Biopharma (...exclusive license to market and distribute the Com...th Teva Pharmaceuticals and Orient Europharma. , ...
... Journal of Radiation Oncology*Biology*Physics Stu...stem Provides Enhanced Image Information for Plann...REAL, March 4 Researchers report in the February ... enhanced image information to enable radiation on...
...., March 9 VirtualHealth Technologies, Inc. (OTC ...ve immediately it,s subsidiary Envoii Healthcare, ...o better reflect it,s focus on eHealth Security pr...t on growing our opportunities in this evolving cl...
... increase in advanced non-small cell, lung cancer ...clitaxel and cisplat...include reductions in chemotherapy-indu...OKYO, March 18 BioNumerik,Pharmaceuticals, Inc. (...ASKA") today announced the results of a Phase III ...
... 2b in Second Quarter of 2008 - - Conferen... DIEGO, March 17 Ardea Biosciences, Inc.,(Nasdaq:...lts from its,ongoing Phase 2a proof-of-concept stu...oside reverse transcriptase inhibitor (NNRTI), in,... Preliminary results from the first two of three ...